Literature DB >> 29035091

Inverse Relationship between Soluble RAGE and Risk for Bronchopulmonary Dysplasia.

John T Benjamin1, Riet van der Meer1, James C Slaughter1, Steven Steele1, Erin J Plosa1, Jennifer M Sucre1, Paul E Moore1, Judy L Aschner2, Timothy S Blackwell1,3, Lisa R Young1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29035091      PMCID： PMC5909162          DOI： 10.1164/rccm.201707-1445LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  11 in total

Review 1.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

Review 2.  Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung.

Authors:  John G Yonchuk; Edwin K Silverman; Russell P Bowler; Alvar Agustí; David A Lomas; Bruce E Miller; Ruth Tal-Singer; Ruth J Mayer
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

Review 3.  Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia.

Authors:  Jessica Y Islam; Roberta L Keller; Judy L Aschner; Tina V Hartert; Paul E Moore
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

4.  Soluble RAGE is deficient in neutrophilic asthma and COPD.

Authors:  M B Sukkar; L G Wood; M Tooze; J L Simpson; V M McDonald; P G Gibson; P A B Wark
Journal:  Eur Respir J       Date:  2011-09-15       Impact factor: 16.671

5.  High-mobility group box-1 protein in tracheal aspirates from premature infants: relationship with bronchopulmonary dysplasia and steroid therapy.

Authors:  Z H Aghai; J G Saslow; C Meniru; C Porter; R Eydelman; V Bhat; G Stahl; S Sannoh; K Pyon; C Hewitt; V Bhandari
Journal:  J Perinatol       Date:  2010-02-25       Impact factor: 2.521

6.  Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD.

Authors:  Lian Wu; Li Ma; Louise F B Nicholson; Peter N Black
Journal:  Respir Med       Date:  2010-11-26       Impact factor: 3.415

Review 7.  The receptor for advanced glycation end products (RAGE) and the lung.

Authors:  Stephen T Buckley; Carsten Ehrhardt
Journal:  J Biomed Biotechnol       Date:  2010-01-19

8.  Prematurity and respiratory outcomes program (PROP): study protocol of a prospective multicenter study of respiratory outcomes of preterm infants in the United States.

Authors:  Gloria S Pryhuber; Nathalie L Maitre; Roberta A Ballard; Denise Cifelli; Stephanie D Davis; Jonas H Ellenberg; James M Greenberg; James Kemp; Thomas J Mariani; Howard Panitch; Clement Ren; Pamela Shaw; Lynn M Taussig; Aaron Hamvas
Journal:  BMC Pediatr       Date:  2015-04-10       Impact factor: 2.125

9.  Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.

Authors:  Matthieu Jabaudon; Raiko Blondonnet; Laurence Roszyk; Bruno Pereira; Renaud Guérin; Sébastien Perbet; Sophie Cayot; Damien Bouvier; Loic Blanchon; Vincent Sapin; Jean-Michel Constantin
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

10.  Associations between maternal and infant morbidities and sRAGE within the first week of life in extremely preterm infants.

Authors:  Lynette K Rogers; Amanda E Graf; Anisha Bhatia; Karen L Leonhart; Reena Oza-Frank
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240
View more
  1 in total

1.  Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis.

Authors:  Carlos Machahua; Ana Montes-Worboys; Lurdes Planas-Cerezales; Raquel Buendia-Flores; Maria Molina-Molina; Vanesa Vicens-Zygmunt
Journal:  Respir Res       Date:  2018-11-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.